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SCHEURINK, A. J. W., H. LEUVENINK AND A. B. STEFFENS. Metabolic and hormonal responses tohypothalamic admin- 
istration ofnorfenfluramine  rats. PHYSIOL BEHAV 53(5) 889-898, 1993.--The ffects of intrahypothalamic administration 
of norfenfluramine (NFFL), an anorectic agent hat increases serotonergic transmission, on plasma concentrations ofglucose, 
free fatty acids (FFA), and their regulating hormones were investigated in resting and exercising rats. Infusion of 5 tzg NFFL in 
0.125 #i aCSF/min into the nucleus paraventricularis of the hypothalamus (PVN) caused asignificant increase of blood glucose, 
plasma epinephrine (E), and corticosterone concentrations. Plasma levels of FFA, insulin, or norepinephrine (NE) remained 
unchanged. Lower doses of NFFL (0.5 and 0.05 #g/min) did not affect peripheral metabolism. The effects of NFFL in the PVN 
were completely prevented by prior administration ofa 5-HTt antagonist, (S)-(-)propranoloi. The exercise-induced increase of 
plasma NE was reduced after prior administration f 5 ug NFFL/min into the PVN. Plasma E responses tended to be increased. 
The exercise-induced alterations inglucose, FFA, corticosterone, and insulin were not affected by NFFL infusion into the PVN. 
The data suggest that activation of serotonergic mechanisms in the PVN might change the neurohormonal response to a stressor 
favouring the release of adrenal hormones above activation of the neuronal branch of the sympathetic nervous ystem. 
Nucleus paraventricularis of the hypothalamus Serotonergic mechanisms 
Norepinephrine Resting and exercising rats 
Free fatty acids Insulin 
FENFLURAMINE (NFFL) is an anorectic agent hat enhances 
serotonergic transmission. It increases the release and it inhibits 
the reuptake of serotonin (5-HT) in serotonergic nerve terminals 
(11,13,27). It also directly activates postsynaptic serotonergic 
receptors when administered in high concentrations (27). The 
anorectic effects of NFFL, i.e., inhibition of total food intake 
and changes in food preference, are mediated by 5-HT receptors 
in the brain, in particular postsynaptic 5-HTt receptors in the 
paraventricular nucleus of the hypothalamus (PVN) (21-23,42). 
Furthermore, ffects of NFFL on peripheral energy metabolism 
also contribute to the anorectic action of NFFL (10,29,30). 
The effects of 5-HT and other serotonergic agents on periph- 
eral energy metabolism are well documented. In general, 5-HT 
influences peripheral metabolism ainly by parallel activation 
of the sympathoadrenal system and the pituitary-adrenocortical 
axis. For example, intravenous administration of the 5-HT~a 
agonists, buspirone and ipsapirone, caused a marked increase 
of blood glucose and concomitant increases of plasma epineph- 
rine (E), norepinephrine (NE), and corticosterone concentrations 
(6,18). Also, IV injection of the 5-HT~, agonist, 8-hydroxy-(di- 
n-propylamino)tetralin (8-OH-DPAT), caused a marked increase 
in baseline blood glucose, plasma E, and corticosterone concen- 
trations (2,7,8). 
Recent experiments by Korte et al. (17) suggest that the effects 
of peripherally administered serotonerglc agents might be me- 
diated by centrally located mechanisms. In these experiments, 
local infusion of minute amounts of 8-OH-DPAT into the PVN 
resulted in consistent increases of both plasma E and cortico- 
sterone concentrations. An increase in blood glucose levels oc- 
curred with some delay. Also, experiments in which depletion 
of 5-HT in the hypothalamus completely blocked the adreno- 
cortical responses following afferent neural stimuli (12) suggest 
that the hypothalamus might play an important role in the effects 
of 5-HT on peripheral metabolism. 
To summarize, substantial evidence indicates that the effects 
of NFFL on food intake behavior and nutrient preference are 
mediated via serotonergic mechanisms in the hypothalamus 
(PVN). The effects of serotonergic agonists on peripheral me- 
tabolism seem also to be mediated via hypothalamic 5-HT re- 
ceptors, most likely located in the PVN (l 2,17). Therefore, it is 
conceivable that hypothalamic pathways might be involved in 
the supposed effects of NFFL on peripheral energy metabolism. 
1 Requests for reprints hould be addressed toAnton Scheurink, Department ofAnimal Physiology, University of Groningen, PO Box 14, 9750 
AA Haren, The Netherlands. 
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In the present study, we investigated this by monitoring the effects 
ofhypothalamic administration f NFFL on the peripheral con- 
centrations of the main energy substrates glucose and free fatty 
acids, and their regulating hormones uch as insulin, catechol- 
amines, and corticosterone in resting and exercising rats. The 
results reveal that central administration ofNFFL markedly af- 
fects peripheral energy metabolism, probably by activation of 
5-HTt receptors in the PVN. 
METHOD 
Animals and Housing 
Male Wistar rats, weighing 300-330 g at the beginning ofthe 
present experiments, were used. The animals were individually 
housed in Plexiglas cages (25 X 25 X 30 cm) at room temperature 
(20 + 2°C), and had continuous access to food (Hope Farm 
chow) and water unless otherwise stated. The rats were main- 
tained on a 12:12 h light:dark regime (0700-1900 h light), and 
they were handled and weighed every day at 0900 h. 
PVN and Heart Cannulation 
Surgery was performed under ether anesthesia. All animals 
were provided with permanent cannulas in the heart and in the 
hypothalamus. Bilateral permanent stainless teel cannulas (in 
mm: 21.0 length, 0.3 o.d., 0.1 i.d.) for drug infusion were stereo- 
tactically implanted into the PVN [in ram: anterioposterior (AP) 
7.2, ventral (V) 2.3, lateral (L) +0.5] according to the coordinates 
of Paxinos and Watson (31). A sterile stainless teel obturator, 
flush with the tip of the cannula, was inserted into each cannula 
between experiments toensure that the cannula remained patent 
and pyrogen free. The cannula end protruding from the skull 
was protected with a 2 IG protective sleeve. A polyethylene cap 
was placed at the protruding end of the protective sleeve to cover 
the cannula. The PVN infusion procedure was similar to tech- 
niques described earlier (39). After termination of the experi- 
ments, brain cannula placement was histologically verified in 
40-~zm brain slices under a light microscope. Only animals with 
correct cannula placement were included in the experiments. 
All animals were also provided with a silicon heart catheter 
(0.95 mm o.d., 0.50 mm i.d.), inserted into the heart through 
the fight jugular vein and externalized on the top of the skull 
according to techniques described earlier (45). This method al- 
lows frequent repeated blood sampling in unanesthetized, un- 
disturbed, freely moving animals (44). The rats were accustomed 
to the brain infusion and blood-sampling procedures three to 
five times before the start of the experiments. The experiments 
started 1 week after insertion of the heart catheter when the rats 
were above their preoperative weights. 
Infusion Solutions 
In all experiments, norfenfluramine (NFFL, Servier, France) 
was infused into the PVN. The drug was dissolved in sterile 
artificial cerebrospinal fluid (aCSF) containing (in raM) 127.64 
NaCI, 2.55 KCi, 1.26 CaClz, and 0.93 MgClz. 6HzO. Fenflura- 
mine was bilaterally infused into the PVN for 17 rain at a rate 
of 0.05, 0.5, or 5 ug in 0.125 ~1 aCSF per minute. The two lower 
doses mimicked concentrations of NFFL that may reach the 
brain after oral administration ofdoses of NFFL that influence 
food intake and peripheral metabolism. The highest (5 ~g) dose 
was comparable to the doses used in previous tudies in which 
feeding behavior was studied (21,22,42). In Experiment 2, 0.3 
mg/kg of the 5-HT~ antagonist, (S)-(-)propranolol (Sigma, St. 
Louis, MO) ( 13,16), dissolved in 0.5 ml saline, was intravenously 
injected prior to and during intrahypothalamical infusion of the 
highest dose of NFFL. 
Exercise 
Exercise was performed in a pool made of stainless teel 
(length 3.00 m, width 0.40 m, and depth 0.90 m) filled 70% with 
water at 33 _+ 2°C. The pool was equipped with a starting plat- 
form (33 X 37 cm) placed 2 cm above the water level. This 
starting platform could be lowered into the water down to the 
bottom of the swimming pool. A water pump (Loewe Silenta, 
Germany) provided a counter current of 0.22 m/s that forced 
the animal to swim continuously. At the end of the exercise 
period, a removable resting platform (20 X 37 cm) at the up- 
stream side of the swimming pool was offered to the swimming 
rat. The rats readily learned to climb on this lighted and warmed 
platform within 2 rain after presentation. Rats were accustomed 
to the exercise conditions before the onset of the actual exper- 
iments. 
Experimental Procedure 
All experiments were performed in the light period between 
0900 and 1200 h. On the experimental day, food was removed 
from the home cages 1.5 h before the start of the experiment. 
Then, 40 min before the first blood sample was taken, the animals 
were connected to two polyethylene PVN infusion tubings (in 
mm: 400 length, 0.61 o.d., and 0.20 i.d.) and one blood-sampling 
tubing (in ram: 300 length, 1.25 o.d. and 0.75 i.d.). Throughout 
the experiment, 10 blood samples (0.6 ml each) were taken for 
determination of the glucose, insulin, catecholamine, and cor- 
ticosterone l vels in blood. After each sample a transfusion of 
0.6 ml of heparinized donor blood was given to avoid dimunition 
of the blood volume with related changes in hemodynamics. 
Donor blood was obtained from undisturbed rats with permanent 
heart catheters. 
In all experiments, two blood samples in a 10-rain interval 
were taken in the home cage of the rat to measure baseline levels 
of the blood components. Then, at t = 0 min, different doses of 
norfenfluramine or control solution (aCSF) were infused into 
the PVN. The infusion was discontinued at t = 17 rain. In Ex- 
periments 1 and 2, blood samples were taken before, during, 
and after hypothalamic nfusion of NFFL at the time points t 
-~ - 11, -1,  5, 10, 15, 21, 25, 35, 45, and 55 rain relative to the 
start of the infusion. 
In Experiment 3, the animal had to perform strenuous ex- 
ercise immediately after the infusion period. For this, the rat 
was transferred from the home cage to the starting platform of 
the swimming pool after termination of the infusion at t = 17 
rain. At t = 20 rain relative to the start of the infusion, the 
starting platform was lowered own to the bottom of the swim- 
ming pool, and the rat had to swim vigourously against he 
counter current for 15 rain. At the end of the exercise period 
(at time point t = 35 min) the resting platform was offered, and 
the animal was transferred back into his homecage. In this ex- 
periment, blood samples were taken at the time points t = - 11 
and -1 (baseline), 5 and 15 (during infusion), 21, 25, 30, and 
35 (during exercise), 45 and 55 rain (postinfusion and postex- 
ercise). 
Chemical Determinations 
Blood samples were immediately transferred tochilled (0°C) 
centrifuge tubes containing 0.1% EDTA as antioxidant and 10 
~1 heparin solution (500 U/ml) as anticoagulant. Blood glucose 
was measured by the ferricyanide method of Hoffman (Tech- 
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nicon Auto Analyzer TMII) with 0.05 ml blood taken from the 
sample. The remaining part was centrifuged for 15 min at 5000 
rpm at 4°C. The supernatant was divided into three parts: 100 
/zl was immediately stored at -80°C for catecholamine mea- 
surements, 100 #1 was used for the FFA assay, and the remaining 
plasma was stored at -30°C for the corticosterone and insulin 
assays. 
Determination ofplasma catecholamine concentrations was 
performed by high pressure liquid chromatography (HPLC) in 
combination with electrochemical detection (ECD) as previously 
described (32) with some minor modifications. The HPLC-ECD 
system included an LKB 2150 pump (LKB Instruments, 
Bromma, Sweden), a Rheodyne injection valve with a 100 ~1 
loop, a reversed-phase nucleosil C18 column (length 25 cm, i.d. 
4 mm) (Gimex, The Netherlands) held at 30°C by a column 
stove (LKB), an ESA 5100 A electrochemical detector with a 
5011 high-sensitive analytical cell and a 5020 guard cell (ESA), 
and a BD 41 two-channel fiat recorder (Kipp). Guard cell po- 
tential in front of the injection valve was +450 mV; the potentials 
of the working electrodes were -50  mV and +350 mV, respec- 
tively. The mobile phase contained 0.05 M Na-acetate, 0.08% 
heptane sulfonic acid, 0.01% EDTA, 0.01% NaC1, and 5% meth- 
anol 95% H20 (pH 4.75). The limit of the detection level for 
epinephrine was 0.010 ng/ml and 0.005 ng/ml for norepineph- 
fine. Intra- and interassay coefficients for the catecholamine 
measurements were 2.25% and 5.36%, respectively. 
Plasma FFA was determined according to the method of An- 
tonis (1) by adapting it for small volumes. Plasma was imme- 
diately extracted and the evaporated extracts were stored at 
-30°C until determination. Rat-specific plasma immunoreactive 
insulin was determined by means of a radioimmunoassay kit 
(NOVO, Denmark). Guinea pig serum M8309 served as anti- 
serum. Duplicate assays were performed on 25-t,1 samples. The 
bound and free t25I-labeled insulin was separated by means of 
a polyethylene glycol solution (23.75% w/w) as described by 
Henquin et al. (14). 
Measurement of plasma corticosterone concentrations was 
performed by HPLC in combination with UV detection. Cor- 
ticosterone was extracted from 30 #1 plasma according to the 
techniques used by Shimuzu et al (41) with minor modifications 
and adaptations for small volumes. 
Experiments 1 and 2: Infusion of Norfenfluramine 
Into the PVN 
The aim of Experiments 1 and 2 was to investigate he effect 
of hypothalamic administration of different doses of norfen- 
fluramine (NFFL) on peripheral concentrations of the energy 
substrates glucose and free fatty acids (FFA), and their regulating 
hormones insulin, catecholamines, and corticosterone in freely 
moving, undisturbed rats. Therefore, in Experiment 1, three 
doses of NFFL (0.05, 0.5, and 5 ~tg/min) were bilaterally infused 
into the PVN at a rate of 0.125 ul/min/cannula for 17 min. In 
the control experiment aCSF was infused into the PVN. Blood 
was sampled as described. The concentrations of blood glucose 
and plasma FFA were determined in all blood samples in all 
experiments. Plasma catccholamine concentrations were deter- 
mined in the blood samples taken at the time points t = - l l, 
-1 ,  5, 15, 25, and 45 min. Likewise, plasma corticosterone levels 
were measured at t = - l, 10, 2 l, and 55 min, and plasma insulin 
concentrations at the time points t = -11, 5, 15, 25, and 45 
min. 
In Experiment 2, the 5-HT~ antagonist, (S)-(-)propranolol 
(27,31), was intravenously injected immediately after the blood 
samples at the time points t = -1  l, -1 ,  5, and l0 rain to char- 
acterize the serotonergic receptors involved in the effects of in- 
trahypothalamical infusion of the highest dose of NFFL on pe- 
ripheral energy substrate metabolism. The experimental design 
was similar to that in Experiment 1, except for the IV admin- 
istration of the 5-HT~ antagonist. Blood samples were taken for 
determination f blood glucose, plasma catecholamines, insulin, 
and corticosterone at the same time points as in Experiment 1. 
Three procedures served as controls: the experiment in which 
the high dose of NFFL was infused into the PVN without ad- 
ministration of the 5-HT~ antagonist, the control experiment in
which aCSF was infused into the PVN, and a control experiment 
in which aCSF was infused into the PVN together with intra- 
venous administration of 0.3 mg/kg of the 5-HT~ antagonist, 
(S)-(-)propranolol. 
Experiment 3: Exercise and NFFL Infusion Into the PVN 
In Experiment 3, the effect of hypothalamic administration 
of the high dose of norfenfluramine (NFFL) on the exercise- 
induced changes in peripheral concentrations of the energy sub- 
strates glucose and free fatty acids (FFA), and their regulating 
hormones insulin and catecholamines, was investigated. Nor- 
fenfluramine (5 #g/min) was bilaterally infused into the PVN 
at a rate of 0.125 ul/min/cannula for 17 rain. Thereafter, the 
animals were subjected to strenuous exercise in the swimming 
pool. In the control experiment aCSF was infused into the PVN. 
Blood glucose and plasma FFA concentrations were determined 
in all blood samples taken. Plasma catecholamines were deter- 
mined in blood samples taken at the time points t = -11, -1 ,  
15, 25, 35, and 45 min. Plasma insulin concentrations were 
measured at the time points t = - 11, 15, 25, and 45 min. 
Data Analysis and Statistics 
Data were expressed as average changes _+ SE from baseline 
values at t = -1  rain before infusion. Within each experiment, 
Wilcoxon matched-pairs signed rank test was used to compare 
the levels of the blood components at each time point relative 
to the baseline level at t = - 1 min. Differences between NFFL- 
infused rats and the control group were determined by applying 
a Mann-Whitney U-test for the changes recorded at each sample 
point. Significance was set at p < 0.05. 
RESULTS 
Experiment 1 
Baseline concentrations of all the blood components are pre- 
sented in Table 1. No differences between the NFFL-treated 
animals and the control group were found for any of the baseline 
measurements. The changes in blood glucose and FFA concen- 
tration as response to intrahypothalamic infusion of various doses 
of NFFL are depicted in the Figs. 1 and 2. Infusion of the two 
low doses of NFFL into the PVN failed to influence blood glucose 
concentrations. Infusion of the high dose (5 #g/kg/min) of NFFL 
caused an immediate increase in blood glucose from a baseline 
level of 109.3 _+ 3.0 mg/dl at t = -1  min up to a maximum of 
142.5 + 6.1 mg/dl at t = 10 min relative to the start of the 
infusion. After termination of the infusion, blood glucose con- 
centrations slowly declined and reached control values at t = 
55 rain. The increase above control values was significant at the 
time points t = 5, 10, 15, 21, 25, 35, and 45 rain. Plasma levels 
of FFA did not change during or after infusion of NFFL or aCSF 
into the PVN. 
The changes in plasma epinephrine (E) and norepinephrine 
(NE) levels during infusion of different doses of NFFL and aCSF 
are presented in the Figs. 3 and 4. Intrahypothalamic infusion 
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TABLE 1 
BASELINE CONCENTRATIONS OF BLOOD GLUCOSE, PLASMA FFA, CATECHOLAMINES, 
AND CORTICOSTERONE AT TIME POINT t = I min IN THE HOME CAGE 
Plasma 
Blood Glucose Plasma FFA Plasma E Plasma NE Corticosterone 










114_+2 0.18_+0.04 0.06_+0.02 0.20_+0.02 30_+4 
116_+4 0.12_+0.02 0.02+__0.01 0.44_+0.14 - -  
107_+2 0.19_+0.05 0.07_+0.02 0.30_+0.07 - -  
109_+3 0.13_+0.02 0.03_+0.01 0.23_+0.03 30_+2 
109 _+ 3 0.17 _+ 0.03 0.06 _+ 0.03 0.27 _+ 0.05 28 _+ 6 
106 _+ 3 0.17 _+ 0.03 0.06 _+ 0.02 0.35 _+ 0.04 24 _+ 3 
110 _+ 2 0.20 _+ 0.04 0.02 ___ 0.01 0.31 _+ 0.04 35 _+ 4 
Number of rats in brackets. 
of the high dose of NFFL altered the concentration of E in 
plasma. The other doses and the control solution failed to have 
any effect. In the experiment in which the high dose of NFFL 
was infused, plasma E concentrations increased from baseline 
values of 34 + 8 pg/ml up to a maximum of 395 + 93 pg/ml at 
t = 5 min. Thereafter, E levels remained moderately increased 
at all time points during and after the infusion of 5 ug/min 
NFFL. Plasma levels of E were significantly increased above the 
values in the control experiment at the time points t = 5, 15, 
25, and 45 min. Plasma levels of NE did not change during or 
after infusion of NFFL or aCSF into the PVN. 
The changes in plasma insulin and corticosterone levels were 
only determined in the experiments in which the high dose of 
NFFL and aCSF were infused into the PVN. The results are 
presented inTable 2 and Fig. 5. Plasma levels of insulin did not 
change during or after infusion of NFFL or aCSF into the PVN. 
Plasma corticosterone concentrations i creased during infusion 
of NFFL from baseline concentrations of 30.3 -+ 2 ng/ml to a 
-O-  csf --~7-- .05 M-g - -0 - -  .5 p.g - -A - -  5 /~.g 












-10  - - , - - , 
-15  0 15 
T; 
- • | - - i - - 
30 45 60 
t ime (min)  
FIG. 1. Blood glucose concentrations in mg/dl before, during, and after 
infusion of different doses of norfenfluramine (NFFL) or aCSF into the 
nucleus paraventricularis of the hypothalamus (PVN). Data re expressed 
as average changes _+_ SE from baseline values at the time point t = - 1 
min in the home cage. * Denotes asignificant change from the values 
in the control animals in which aCSF was infused. Infusion time is in- 
dicated by horizontal bar. 
maximum of 49.6 + 5 ng/ml at t = 55 min. The differences with 
the control experiment were significant at the time points t = 
10, 21, and 55 min. 
Experiment 2 
Baseline concentrations of the blood components measured 
in Experiment 2 are also presented inTable 1. The changes from 
baseline levels are depicted in Figs. 6-10 and Table 2. Injection 
of the 5-HT, antagonist, (S)-(-)propranolol, had no effect on 
baseline concentrations of the blood components measured. 
Furthermore, no changes in any of the blood components mea- 
sured were observed after infusion of either aCSF, or the com- 
bination of (S)-(-)propranolol and intrahypothalamic aCSF. 
Administration of (S)-(-)propranolol prior to a high dose of 
intrahypothalamic NFFL infusion completely prevented the in- 
crease in E as seen in Experiment 1during and after intrahy- 
pothalamic infusion of NFFL. Blood glucose levels increased 
only moderately during NFFL infusion after prior administration 
of (S)-(-)propranolol. Finally, prior administration of (S)- 
(-)propranolol could not prevent he NFFL-induced increase 
in plasma corticosterone levels. The differences between the ex- 
-O -  cs f  - -x T-- .05 o ,g - -O- -  .5 P,g - -&- -  5 /~g 
n=6 n=8 n=6 n=8 
0.35  
0 .25"  
• 0 .15"  
< 0 .05 '  
LL 
LL 
<3 -0 .05 ,  
-0 .15  - - , - - • . . . . .  " " 
-15  0 15 ~0 45  60 
t ime ( ra in )  
FIG. 2. Plasma free fatty acid (FFA) concentrations in #Eq/ml before, 
during, and after infusion of different doses of norfenfluramine (NFFL) 
or aCSF into the PVN. Data are expressed asin Fig. 1. 
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-o -  cs f  - -v - -  .05  /~g- -0 - -  .5  ~ -a - -  5 /~0 
n----6 n=3 n=3 n=5 
0.80 




o.oo. |~- - -  =-=-=:~ 8 
<3 
-0.20 - - • . - , - - , - - , - 
-15  0 15 30  45  60 
t ime (min) 
FIG. 3. Plasma epinephrine (E) concentrations i  ng/ml before, during, 
and after infusion of different doses of norfenfluramine (NFFL) or aCSF 
into the PVN. Data are expressed asin Fig. I. 
periments in which NFFL was infused with and without he 
serotonergic antagonist were significant at the time points t = 5 
and 10 rain for glucose, and at t = 5 and 45 min for E. 
Experiment 3 
In Experiment 3, the effect of hypothalamic administration 
of the high dose of norfenfluramine (NFFL) or aCSF on the 
exercise-induced changes in peripheral concentrations of glucose, 
FFA, insulin, and catecholamines was investigated. Baseline 
measurements aredepicted in Table 1; the changes from baseline 
are presented inFigs. I 1-14 and Table 2. Plasma concentrations 
of any of the blood components measured did not change during 
infusion of aCSF into the PVN. Exercise induced an increase 
in blood glucose, plasma FFA, NE, and E concentrations. Plasma 
insulin levels were decreased uring swimming. The exercise- 
induced changes in the blood components were very similar to 
the changes described for the control animals in previous tudies 
from our laboratory (36,37). Intrahypothalamic infusion of 
NFFL before exercise increased blood glucose and plasma E 
concentrations, and failed to influence plasma concentrations 
TABLE 2 
PLASMA INSULIN CONCENTRATIONS _+ SE IN #U/ml 
IN EXPERIMENTS l, 2, AND 3 
Time 
(min) -11 5 15 25 45 
Experiments 1 and 2 
aCSF[5] 30+6 34+5 42_+9 40_ 7 43_+6 
NFFL3[5] 38+5 42+5 44+6 46_ 6 40+5 
Prop [5] 37+7 38+9 39+8 42_ 8 38+9 
Experiment 3 
aCSF[5] 37_+5 - -  39+6 22_ 5 21+8 
NFFL3[5] 36+7 - -  32+2 26+_ 11 19+4 
Number of rats in brackets. 
of FFA, NE, and insulin. These results were equal to the data 
obtained in Experiment I. Exercise following NFFL infusion 
further enhanced blood glucose and plasma E levels. Plasma 
FFA and NE levels were also increased uring exercise after 
NFFL infusion. To compare the exercise-induced changes in 
the aCSF- and NFFL-treated groups, the effects of swimming 
on glucose, E, and corticosterone concentrations were calculated 
as changes from the data at corresponding time points in the 
nonexercising animals in Experiment 1. It means that, for each 
time point, the value in the nonexercising animals receiving aCSF 
or NFFL was subtracted from the value at the corresponding 
time point in the exercising animals receiving aCSF or NFFL. 
The results of the calculations for glucose and E are presented 
in Figs. 15 and 16. No differences between the NFFL- and the 
aCSF-treated animals with regard to the exercise-induced hanges 
in glucose, FFA, E, or insulin were found. In contrast, he ex- 
ercise-induced increase in plasma NE levels was significantly 
lower in the NFFL-treated animals when compared with the 
aCSF-infused control rats. In the latter group, plasma NE levels 
increased up to 2.7 + 0.3 ng/ml at t = 45 rain, which is similar 
to control values obtained in previous tudies in our lab (36). 
On the other hand, the exercise-induced increase in plasma NE 
remained relatively low in the NFFL-treated animals; the max- 
imum of 2.0 -+ 0.3 ng/ml after 15 min of swimming was markedly 
-O-  cs f  - -v - -  .05  /~g- - [3 - -  .5  / zg  - -A - -  5 /~g 
n=5 n=3 n=3 n=5 
3 
O~ 










. . , . . , - . , - . , . . 
0 15 30  45  60 
t ime (min) 
FIG. 4. Plasma norepinephrine (NE) concentrations i  ng/ml before, 
during, and after infusion of different doses of norfenfluramine (NFFL) 
or aCSF into the PVN. Data are expressed asin Fig. I. 
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FIG. 5. Plasma corticosterone concentrations i  #g/dl before, during, 
and after infusion of norfenfluramine (NFFL) or aCSF into the PVN. 
Data are expressed asin Fig. I. 
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FIG. 6. Blood glucose concentrations in mg/dl before, during, and after 
intrahypothalamic infusion of 5 ug of norfenfluramine (NFFL) with or 
without previous intravenous administration f the 5-HTt antagonist, 
(S)-(-)propranolol. Data are expressed as average changes _+ SE from 
baseline values at the time point t = - l rain in the home cage. * Denotes 
a significant change from the values in the animals in which the 5-HT~ 
antagonist was infused. Infusion time is indicated by horizontal bar. The 
absolute control experiment in which aCSF was infused is also depicted 
in this graph. 
reduced in comparison to the concentrations reached in the 
control group (Fig. 14). The differences between the NFFL- and 
the aCSF-treated animals were significant at time point t = 25 
min, 5 min after the start of exercise. 
DISCUSSION 
The anorectic drug, norfenfluramine (NFFL), acts via en- 
hancement of serotonergic transmission. It increases the release 
and it inhibits the reuptake of serotonin (5-HT) in serotonergic 
nerve terminals (11,13,30). In the present experiments, intra- 
hypothalamic infusion of a relatively high dose of NFFL led to 
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FIG. 8. Plasma epinephrine (E) concentrations i  ng/ml before, during, 
and after intrahypothalamic infusion of 5 ug ofnorfenfluramine (NFFL) 
with or without previous intravenous administration f the 5-HTI an- 
tagonist, (S)-(-)propranolol. Data are expressed as in Fig. 6. 
a marked increase of blood glucose and plasma concentrations 
of the adrenal hormones epinephrine (E) and corticosterone. 
Administration of the 5-HT~ antagonist, (S)-(-)propranolol, 
prior to intrahypothalamic infusion of NFFL completely pre- 
vented the NFFL-induced increases of E and, partly, glucose. 
Prior administration of (S)-(-)propranolol did not prevent the 
NFFL-induced increase of plasma corticosterone concentrations. 
Plasma norepinephrine (NE) and free fatty acid (FFA) levels 
remained at baseline values during and after infusion of NFFL 
into the PVN. The results are in agreement with the effects ob- 
served by Korte et al. (17), who found that intrahypothalamic 
administration of a 5-HT~a selective agonist, 8-OH-DPAT, re- 
suited in immediate increases of both plasma E and corticoste- 
rone concentrations. They also observed an increase in blood 
glucose levels, no changes in plasma NE concentrations, whereas 
plasma FFA and insulin concentrations were not measured in 
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FIG. 7. Plasma free fatty acid (FFA) concentrations in pEq/ml before, 
during, and after intrahypothalamic infusion of 5 pg of noffenfluramine 
(NFFL) with or without previous intravenous administration f the 5- 
HT~ antagonist, (S)-(-)propranolol. Data are expressed as in Fig. 6. 
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FIG. 9. Plasma norepinephrine (NE) concentrations in ng/ml before, 
during, and after intrahypothalamic infusion of 5 jzg of norfenfluramine 
(NFFL) with or without previous intravenous administration f the 5- 
HT, antagonist, (S)-(-)propranolol. Data are expressed as in Fig. 6. 
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FIG. 10. Plasma corticosterone concentrations in #g/dl before, during, 
and after intrahypothalamic infusion of 5 #g of norfenfluramine (NFFL) 
with or without previous intravenous administration f the 5-HT] an- 
tagonist, (S)-(-)propranolol. Data are expressed as in Fig. 6. 
that study (17). The present data on the effects of relatively low 
doses of centrally administered 8-OH-DPAT and NFFL on pe- 
ripheral energy substrate metabolism were remarkably similar 
to the effects observed by others after peripheral dministration 
of much higher doses of 5-HT and other serotonergic agents 
(2,6-8,18), suggesting that in particular central serotonergic 
mechanisms are involved (23). 
Based on these data, the following underlying mechanism 
for the NFFL-induced increases of plasma E and glucose might 
be hypothesized. First, hypothalamic administration of NFFL 
will lead to increased turnover of serotonin in the PVN, leading 
to stimulation of, particularly, postsynaptic 5-HTu receptors. 
Activation of these PVN 5-HT~ receptors causes the activation 
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FIG. 11. Blood glucose concentrations i  mg/dl before, during, and after 
infusion of 5 #g of norfenfluramine (NFFL) or aCSF into the PVN and 
exercise. Data are expressed as average changes _+ SE from baseline values 
at the time point = - l min in the home cage. ~r Denotes asignificant 
change from the values in the control animals in which aCSF was infused. 
Infusion time is indicated by horizontal bar. Exercise period is indicated 
by dotted area. 
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FIG. 12. Plasma free fatty acid (FFA) concentrations in ~Eq/mi before, 
during, and after infusion of 5 ttg of noffenfluramine (NFFL) or aCSF 
into the PVN and exercise. Data are expressed as in Fig. l 1. 
of a hypothalamic-adrenalmedullary pathway, leading to an in- 
creased release of the adrenal hormone pinephrine. As a con- 
sequence, blood glucose levels increased, caused by the stimu- 
latory effect of increased E levels on hepatic glucose production 
(37,40,43). 
Hypothalamic administration of NFFL increased plasma 
corticosterone concentrations in the present study. This confirms 
earlier findings ( 12,17) that serotonergic mechanisms in the PVN 
may play a role in the activation of the hypothalamic-pituitary- 
adrenal (HPA) axis. The increase of corticosterone outflow is 
presumably mediated by 5-HT~a receptors in the PVN, because 
Korte et al. (17) showed that intrahypothalamic infusion of the 
selective agonist, 8-OH-DPAT, leads to increased levels of cor- 
ticosterone in plasma. However, prior administration of the 5- 
HTI antagonist, (S)-(-)propranoiol, could not prevent the 
NFFL-induced increase of plasma corticosterone l vels in the 
present study. This suggests that besides 5-HT~ receptors, also 
other subtypes of hypothalamic serotonergic receptors might play 
0.80 
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FIG. 13. Plasma epinephrine (E) concentrations i  ng/ml before, during, 
and after infusion of 5 ug of norfenfluramine (NFFL) or aCSF into the 
PVN and exercise. Data are expressed as in Fig. 11. 
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FIG. 15. Calculated exercise-induced changes in blood glucose levels in 
mg/dl after hypothalamic infusion of 5 ug of norfenfluramine (NFFL) 
or aCSF into the PVN. 
a role in the NFFL-induced increase in plasma corticosterone 
concentrations. Data in the literature suggest hat 5-HT2 recep- 
tors might be involved (47). 
Now the question arises as to which neuronal or hormonal 
connections, arising from the 5-HT, receptors in the PVN and 
activating both the sympathoadrenal system and the pituitary- 
adrenocortical axis, might be involved. The pathways containing 
corticotropin releasing hormone (CRH) as the main neurotrans- 
mitter might be the major candidate for this function for several 
reasons. First, neuroanatomical studies revealed that CRH-con- 
taining neurons with cell bodies in the PVN synaptically interact 
with serotonergic axons (24). The CRH-containing neurons in 
the PVN directly project to areas in the brain such as the central 
amygdala, the autonomic areas in the brain stem, as well as the 
locus coeruleus (35,46). These areas are directly connected with 
the motor neurons of the sympathetic nervous system in the 
intermediolateral column in the spinal cord and might play an 
important role in the regulation sympathoadrenal outflow. In 
addition, the CRH-containing neurons also project to the median 
eminence, the main (neuro)hormonal pathway between the hy- 
pothalamus and the pituitary (28,33,34). Second, physiological 
evidence for a role of CRH-containing neurons in the PVN in 
the control of E and corticosterone studies has emerged from a 
number of studies in which stimulation or lesioning of the PVN 
have led to alterations in the outflow of CRH and ACTH 
(5,25,26), and from studies in which intracerebral and/or pe- 
ripheral administration of CRH specifically changed plasma 
levels of E and corticosterone (3,4). Finally, recent experiments 
by Le Feuvre et al. (20) revealed that pretreatment with CRH 
antibodies could prevent the thermogenic and anorectic effects 
of centrally administered exfenfluramine. 
Hypothalamic infusion of NFFL increased plasma E levels 
without any increase of plasma NE concentrations. This means 
that activation of serotonergic mechanisms in the PVN selec- 
tively activates the adrenal medullary branch of the sympa- 
thoadrenal system• It might be hypothesized that hypothalamic 
serotonergic mechanisms particularly play a role in the central 
nervous response to emotional stress• Direct evidence for this 
emerged from a study in which lesioning of the PVN reduced 
the normal stress-induced increase of plasma E but not NE (19). 
Indirect evidence is provided by studies in which administration 
of CRH mediated the E response to several stressful simuli (4), 
and studies that revealed that emotional stress causes a selective 
activation of the adrenal medulla without any increase of the 
outflow of NE from the sympathetic nerve endings (9,38). Fur- 
ther evidence for a role of serotonergic mechanisms in the PVN 
in the sympathoadrenal response to stress derives from Exper- 
iment 3, in which infusion of NFFL into the PVN markedly 
reduced the exercise-induced increase of plasma NE levels. These 
results are in concert with our recent findings that emotional 
stress leads to a reduction in the outflow of neuronal NE during 
exercise (38). 
In Experiment 3, intrahypothalamic nfusion of NFFL resulted 
in increases of blood glucose and plasma E concentrations that 
were similar to the changes observed in Experiment 1. Exercise 
further enhanced the levels of these blood components. However, 
when calculated as changes from nonexercising controls in Ex- 
periment 1, the actual exercise-induced changes in glucose and E 
levels were not different between the NFFL- and the aCSF-treated 
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FIG. 16. Calculated exercise-induced changes in plasma epinephrine (E) 
levels in ng/rnl after hypothalamic infusion of 5 #g of norfenfluramine 
(NFFL) or aCSF into the PVN. 
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animals. This suggest that serotonergic mechanisms in the PVN 
are not directly involved in the normal exercise-induced changes 
in the aforementioned blood components. 
In summary, the results of the present study reveal that in- 
fusion of the anorectic agent, norfenfluramine (NFFL), into the 
nucleus paraventricularis of the hypothalamus (PVN) markedly 
increases plasma E, corticosterone, and blood glucose concen- 
trations in unanesthetized, freely moving, and undisturbed rats. 
In addition, intrahypothalamic administration f NFFL reduces 
the normal exercise-induced increase in plasma norepinephrine 
(NE) concentrations. It is concluded that activation of 5-HT~ 
receptors in the PVN leads to a parallel activation of the sym- 
pathoadrenal system and the pituitary-adrenocortical axis. Cor- 
ticotropin releasing hormone (CRH)-containing pathways arising 
from the PVN and projecting to the pituitary and the sympathetic 
motor nuclei in the brain stem might serve as an intermediate 
factor. A dissociation occurs within the sympathoadrenal re- 
sponse to hypothalamic NFFL infusion, leading to selective ac- 
tivation of the adrenal medullary branch and concomitant re- 
duction of neuronal outflow of NE. It is hypothesized that 
serotonergic mechanisms in the PVN might be involved in the 
central nervous response to emotional stress. 
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